View Older Stories View More Recent Stories

May 12, 2024 08:20PM Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
May 8, 2024 04:05PM Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
Apr 15, 2024 07:30AM Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
Apr 11, 2024 07:31AM Zai Lab (ZLAB) Statement on Executive Management Team’s Agreement on Share Activities
Apr 11, 2024 07:30AM Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
Apr 2, 2024 07:30AM Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
Apr 1, 2024 07:31AM Bristol-Myers Squibb (BMY) Announces KRYSTAL-12 Confirmatory Trial of KRAZATI Meets Primary Endpoint
Apr 1, 2024 07:30AM Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRA
Mar 27, 2024 09:29AM Zai Lab (ZLAB) Partner Novocure (NVCR) Announces METIS Phase 3 Clinical Trial Met Primary Endpoint
Mar 27, 2024 09:29AM Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Me
Mar 13, 2024 07:05PM Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
Mar 6, 2024 04:01PM Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
Mar 6, 2024 07:30AM Zai Lab Announces Participation in March Investor Conference
Feb 27, 2024 04:05PM Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
Jan 25, 2024 04:15PM Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
Jan 10, 2024 05:12PM Zai Lab Limited (ZLAB) Announces Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
Jan 10, 2024 05:12PM Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
Dec 19, 2023 07:30AM Zai Lab Announces Participation in January Investor Conference
Dec 13, 2023 08:53AM Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
Dec 13, 2023 03:16AM Zai Lab Limited (ZLAB) Announces First Listing of VYVGART, Other Updates in China’s National Reimbursement Drug List
Dec 12, 2023 11:10PM Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List
Nov 7, 2023 04:05PM Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
Jul 6, 2023 04:05PM Zai Lab Limited (ZLAB) Promotes Yajing Chen to CFO
Jul 6, 2023 04:05PM Zai Lab Announces Promotion of Yajing Chen to Chief Financial Officer
Jun 30, 2023 09:25AM Zai Lab Limited (ZLAB) and argenx Announce Approval of VYVGART for Generalized Myasthenia Gravis in China
Jun 30, 2023 09:22AM Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
Jun 14, 2023 11:07AM ZLAB INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation – ZLAB
Jun 6, 2023 08:07AM Zai Lab (ZLAB) and Novocure (NVCR) Report LUNAR Phase 3 Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival
Jun 6, 2023 08:05AM Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lu
Apr 27, 2023 07:32AM Zai Lab Limited (ZLAB) Enters Partnership and License Agreement with MediLink Therapeutics for Antibody-Drug Conjugate Program in Oncology
Apr 27, 2023 07:30AM Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology
Apr 26, 2023 10:25AM Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 20, 2023 07:30AM Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023
Apr 11, 2023 08:03AM Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting
Mar 20, 2023 06:35AM Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
Mar 1, 2023 04:01PM Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates
Feb 28, 2023 07:30AM Zai Lab Announces Participation in March Investor Conferences
Feb 22, 2023 04:30PM Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
Feb 22, 2023 07:30AM Zai Lab Limited (ZLAB) Announces NDA Acceptance of Sulbactam-Durlobactam
Feb 22, 2023 07:30AM Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
Feb 9, 2023 07:30AM Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023
Jan 31, 2023 07:30AM Zai Lab Announces Participation in February Investor Conferences
Jan 30, 2023 07:30AM Zai Lab Limited (ZLAB) Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA
Jan 30, 2023 07:30AM Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA
Jan 18, 2023 07:50AM Zai Lab Limited (ZLAB) Announces Inclusion of QINLOCK and NUZYRA in China’s National Reimbursement Drug List
Jan 18, 2023 07:49AM Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
Jan 9, 2023 07:33AM Zai Lab Limited (ZLAB) Appoints Michel Vounatsos To Its Board
Jan 9, 2023 07:30AM Zai Lab Appoints Michel Vounatsos To Its Board of Directors
Jan 5, 2023 07:35AM Zai Lab Limited (ZLAB) and Novocure (NVCR) Announce LUNAR Study Met Primary Overall Survival Endpoint
Jan 5, 2023 07:34AM Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
View More Recent Stories View Older Stories